Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Plus SOX vs SOX in Locally Advanced Esophagogastric Junction Adenocarcinoma
NCT04989985Phase 2Recruiting
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- Sep 2021
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in esophagogastric junction adenocarcinoma (GEJA), sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Started Sep 2021; status: recruiting.
02
Drugs
sintilimab
03
Conditions
esophagogastric junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT04989985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04989985.